Table 1.
Demographic and baseline clinical characteristics
| Vortioxetine (n = 39) | Placebo (n = 41) | |
|---|---|---|
| Demographic and clinical characteristics | ||
| Women, n (%) | 28 (71.8) | 30 (73.2) |
| Age (years) | 47.3 (11.0) | 46.9 (13.7) |
| Ethnicity, n (%) | ||
| Caucasian | 39 (100) | 40 (97.6) |
| Black or African-American | 0 | 1 (2.4) |
| BMI (kg/m2) | 25.0 (3.7) | 24.6 (3.5) |
| Duration of current episode (days) | 150.6 (50.2) | 165.5 (77.1) |
| Median (days) | 140 | 131 |
| Number of previous episodes | 3.4 (2.0) | 2.8 (1.7) |
| Range | 1-10 | 1-8 |
| Treatment at study entry | ||
| SSRI, n (%) | 26 (66.7) | 29 (70.7) |
| SNRI, n (%) | 13 (23.3) | 12 (29.3) |
| Baseline clinical assessments | ||
| MADRS total score | 35.6 (3.4) | 34.7 (2.7) |
| MADRS-6 subscale score | 23.4 (2.3) | 22.9 (2.2) |
| CGI-S score | 5.1 (0.6) | 5.1 (0.5) |
| HADS-D score | 16.5 (3.2) | 15.7 (3.2) |
| HADS-A score | 12.1 (3.0) | 11.8 (3.6) |
| PGIC score | 1.4 (0.6) | 1.5 (0.6) |
Mean (SD) reported unless otherwise specified. Demographic and clinical characteristics based on all treated patients; clinical assessments based on the full-analysis set.
CGI-I, Clinical Global Impressions – Improvement; CGI-S, Hospital Anxiety and Depression Scale – Depression; HADS-A, Hospital Anxiety and Depression Scale – Anxiety; MADRS, Montgomery–Åsberg Depression Scale; PGI-C, patient global impression of change; SNRI, serotonin-norepinephrine reuptake inhibitors; SSRI, selective serotonin reuptake inhibitors.